Gedeon Richter

August 22, 2018

Esmya rejection hits Allergan's streamlining

A US FDA complete response letter has dealt Allergan’s hopes of finding a buyer for its women’s health unit a serious blow.

Therapy focus – Abbvie moves into pole position in women’s health

December 15, 2017

Upcoming events – Approval decision for Aclaris and Elagolix’s phase III data

September 29, 2017

Upcoming events – FDA’s date for Mylan’s Neulasta copy and Rhopressa’s panel

March 31, 2016

Defitelio highlights a regulatory fault line

February 12, 2016

Upcoming events – Allergan's uterine fibroid pill and BioMarin's Kuvan follow-on

July 05, 2011

Big pharma enjoys stock market recovery in first half of year

June 17, 2011

Forest's financial profile deserves scrutiny

October 07, 2010

PregLem acquisition adds weight to spin out debate

January 06, 2010

Drug stocks recover in 2009 with generics leading the way

July 01, 2009

Generic players continue to impress in the first half

Load More